Skip to main content
Premium Trial:

Request an Annual Quote

Beyond Genomics Closes $11M in Private Round

NEW YORK, Feb. 13 - Beyond Genomics on Wednesday said it has secured $11 million in a new round of private equity financing.

This round, fed by AGTC Funds/Flagship Ventures and Gilde Biotechnology and Nutrition, brings to $21 million the total cash Beyond Genomics has pocketed since it opened its doors in November 2000.

"The infusion of new equity capital will allow us to dramatically expand our in-house drug discovery research programs, while also expanding our collaborative programs with pharmaceutical partners," said Stephen Ober, the company's president.

GenomeWeb reported last week that Waltham, Mass.-based Beyond Genomics had struck a research collaboration with DiaDexus, marking the second collaboration for the fledgling firm.

Beyond Genomics' maiden deal, inked last May with Elan Pharmaceuticals, was designed to apply its systems biology techniques to Elan's Alzheimer's research. The DiaDexus partnership, which deals with cancer, will be "a little different," Ober said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.